Endoscopic correction of vesicoureteral reflux in children

Introduction: dextranomer/hyaluronic (dx/ha) acid is the only tissue-augmenting agent approved by the food and drug administration (fda) for the vesicoureteral reflux (vur) treatment. objectives: we aimed to evaluate short-term outcomes of the dx/ha in patients who had undergone subureteric injection. patients and methods: in this study, 30 patients with vur diagnosis who had indications for open surgery were enrolled in the study. patients underwent subureteric dx/ha injection. additionally patients underwent a one-year follow up period, subsequently. follow up included urine analysis, urine cultures and kidney and urinary tract ultrasonography study. results: of a total 30 patients, 8 patients (27%) were male and 22 patients (73%) were female. the mean age of patients was 25.19 ± 0.70 months. postoperative vur resolution was observed in 28 patients (93.3%). moreover, during one year follow up, urinary tract infection (uti) was not reported in patients. however, recurrent vur was detected in 8 patients (27%) during ultrasonography follow up. analysis showed no significant difference of recurrence in vur between males and females (p=0.285) and vur severity (p=0.1). there was a significant relationship between recurrent uti history before intervention and vur recurrence after subureteric injection (p=0.007). conclusion: dx/ha acid subureteric injection provides acceptable resolution rate among vur patients, but its biodegradability causes vur recurrence during one-year follow up.